CDMO/CMO Roundup: Cambrex Creates Center of Excellence; AGC Biologics Expands

By Akia Thorpe -

September 27, 2018

Cambrex, a contract manufacturing organization of small-molecule active pharmaceutical ingredients (APIs), and AGC Biologics, a Bothell, Washington-based contract development and manufacturing organization of biologics, have announced plans to expand contract manufacturing operations with new facility investments.

Chemicals/Chemical APIs

Cambrex To Establish Center of Excellence for Process Development and Clinical Supply
Cambrex plans to establish a center of excellence for API clinical supply and process development at its site in High Point, North Carolina. Cambrex will acquire its currently leased 35,000-square-foot facility, as well as an adjacent 45,000-square-foot building, which will be fitted out with kilo-scale and pilot-scale vessels, continuous reaction production, and chemistry, engineering, and analytical development laboratories.

Source: Cambrex


Biologics Manufacturing

AGC Biologics To Build New Biomanufacturing Facility in Japan
AGC Biologics plans to establish a new process development and manufacturing facility in Chiba, Japan. The new facility, which is expected to be operational in the second half of 2019, will contain single-use bioreactors at the 500- and 2,000-liter scale and will be suited for producing monoclonal antibodies, fusion proteins, and other types of therapeutic proteins.

Source: AGC Biologics